COVID-19’s Potential Effect on Dementia Risk: James E. Galvin, MD, MPH
The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the current understanding of COVID-19 and its associations with cognitive decline and Alzheimer disease.
"There’s rampant COPD [chronic obstructive pulmonary disease] in adults and asthma in children because of the particulate air pollution. We know that COPD may be a risk factor for Alzheimer disease. COPD accelerating COVID, both together, may contribute to worsening outcomes in terms of Alzheimer disease.”
Much has been learned about COVID-19 since the beginning of the pandemic; however, questions remain about the long-term impact of the virus. Specific neurological symptoms previously documented in people with COVID-19 include loss of smell, inability to taste, muscle weakness, tingling or numbness in the hands and feet, dizziness, confusion, delirium, seizures, and stroke. Although there is a consensus that these can occur, experts do not know how the virus causes such neurological symptoms.
The knowledge of COVID-19 and its associations with cognition, Alzheimer disease (AD) and other related dementias, is relatively limited at this point. Pooled data from 3 presentations at the
REFERENCE
COVID-19 associated with long-term cognitive dysfunction, acceleration of Alzheimer’s symtpoms. News release. Alzheimer’s Association. July 29, 2021. Accessed September 1, 2021. https://www.alz.org/aaic/releases_2021/covid-19-cognitive-impact.asp
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.